Clinical and Biochemical Responses to SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors in Patients With Rheumatic Heart Disease and Heart Failure.
- 1Cardiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, IND.
Abstract
Background
Rheumatic heart disease (RHD) remains the third most common cause of heart failure in India, which bears the highest global burden of RHD. Left untreated or poorly managed, RHD culminates in heart failure, posing substantial challenges for clinical management. Despite advances in interventional management, the therapeutic landscape for heart failure in patients with RHD remains inadequately explored, particularly with respect to sodium-glucose cotransporter-2 (SGLT2) inhibitors.Methods
This hospital-based study enrolled 90 patients with chronic RHD and New York Heart Association (NYHA) functional class II-IV heart failure. All patients received standard heart failure therapy, with SGLT2 inhibitors added according to the study protocol. Baseline evaluation included clinical assessment and measurement of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Patients were followed for three months, and changes in NYHA functional class and serum NT-proBNP levels were assessed.Results
At three months following initiation of SGLT2 inhibitor therapy, significant improvements were observed in both clinical and biochemical parameters. The mean serum NT-proBNP level decreased significantly from 1,687.0 ± 897.8 pg/mL at baseline to 1,212.6 ± 606.6 pg/mL at follow-up (p < 0.001). Improvement in NYHA functional class was noted in 44 (48.9%) patients, while 41 (45.6%) patients remained clinically stable with no change in functional class. Five (5.6%) patients experienced worsening of NYHA functional class during follow-up. Overall, the change in NYHA functional class was statistically significant (p < 0.001).Conclusion
Our findings suggest that the addition of SGLT2 inhibitors to standard heart failure therapy was associated with significant improvement in NYHA functional class and a significant reduction in NT-proBNP levels over three months.
Related
- Clinical Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors After Transcatheter Aortic Valve Replacement in Patients With Diabetes: A Global Retrospective Study
- Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
- Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review
- Gene‐Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium‐Glucose Cotransporter‐2 Inhibitors
- Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Decompensated Heart Failure: Efficacy, Safety, and Implementation in Stabilized Patients
BibTeX
@article{asthana2026clinical,
title = {{Clinical and Biochemical Responses to SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors in Patients With Rheumatic Heart Disease and Heart Failure.}},
author = {Aman Asthana and Diganta Buragohain and Preethi Caleb Harris and Amish Shikoh and Amit Malviya and Animesh Mishra},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116770},
url = {https://europepmc.org/article/MED/42921474},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical and Biochemical Responses to SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors in Patients With Rheumatic Heart Disease and Heart Failure.
AU - Aman Asthana
AU - Diganta Buragohain
AU - Preethi Caleb Harris
AU - Amish Shikoh
AU - Amit Malviya
AU - Animesh Mishra
PY - 2026
DA - 2026/09/23
JO - Cureus
DO - 10.7759/cureus.116770
UR - https://europepmc.org/article/MED/42921474
AB - Background Rheumatic heart disease (RHD) remains the third most common cause of heart failure in India, which bears the highest global burden of RHD. Left untreated or poorly managed, RHD culminates in heart failure, posing substantial challenges for clinical management. Despite advances in interventional management, the therapeutic landscape for heart failure in patients with RHD remains inadequately explored, particularly with respect to sodium-glucose cotransporter-2 (SGLT2) inhibitors.Methods This hospital-based study enrolled 90 patients with chronic RHD and New York Heart Association (NYHA) functional class II-IV heart failure. All patients received standard heart failure therapy, with SGLT2 inhibitors added according to the study protocol. Baseline evaluation included clinical assessment and measurement of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Patients were followed for three months, and changes in NYHA functional class and serum NT-proBNP levels were assessed.Results At three months following initiation of SGLT2 inhibitor therapy, significant improvements were observed in both clinical and biochemical parameters. The mean serum NT-proBNP level decreased significantly from 1,687.0 ± 897.8 pg/mL at baseline to 1,212.6 ± 606.6 pg/mL at follow-up (p < 0.001). Improvement in NYHA functional class was noted in 44 (48.9%) patients, while 41 (45.6%) patients remained clinically stable with no change in functional class. Five (5.6%) patients experienced worsening of NYHA functional class during follow-up. Overall, the change in NYHA functional class was statistically significant (p < 0.001).Conclusion Our findings suggest that the addition of SGLT2 inhibitors to standard heart failure therapy was associated with significant improvement in NYHA functional class and a significant reduction in NT-proBNP levels over three months.
SN - 2168-8184
ER -